Targeted therapy with imatinib and other selective tyrosine kinase inhibitors has transformed
the treatment of chronic myeloid leukemia. Unlike chronic myeloid leukemia, chronic …

B cell receptor (BCR) signaling plays an important pathogenic role in chronic lymphocytic
leukemia (CLL) and B cell lymphomas, based on structural restrictions of the BCR, and BCR …

Chronic lymphocytic leukemia (CLL), an incurable malignancy of mature B lymphocytes,
involves blood, bone marrow, and secondary lymphoid organs such as the lymph nodes …

The B-cell receptor (BCR) is a key survival molecule for normal B cells and for most B-cell
malignancies. Recombinatorial and mutational patterns in the clonal immunoglobulin (Ig) of …

The genetic lesions identified to date do not fully recapitulate the molecular pathogenesis of
chronic lymphocytic leukemia (CLL) and do not entirely explain the development of severe …

NF-κB may be a potential therapeutic target for acute myelogenous leukemia (AML)
because NF-κB activation is found in primitive human AML blast cells. In this report, we …

BIRC3 is a recurrently mutated gene in chronic lymphocytic leukemia (CLL) but the
functional implications of BIRC3 mutations are largely unexplored. Furthermore, little is …

The protein kinase Syk is a key mediator of proximal B-cell receptor (BCR) signaling.
Following antigen stimulation, Syk is recruited to the BCR and becomes activated by …

Non-coding RNAs are much more common than previously thought. However, for the vast
majority of non-coding RNAs, the cellular function remains enigmatic. The two long non …

The B cell receptor (BCR) pathway has been identified as a potential therapeutic target in a
number of common B cell malignancies, including chronic lymphocytic leukemia, diffuse …